Press Releases - Page 3 of 5 - F-Star Therapeutics Inc.

Mar 29, 2021

F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update »

Mar 16, 2021

F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021 »

Mar 4, 2021

F-star Therapeutics to Present at Upcoming Investor Conferences »

Jan 20, 2021

F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1 »

Jan 6, 2021

F-star Therapeutics to Participate in Upcoming Conferences »

Jan 5, 2021

F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration »

Jan 4, 2021

F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial »

Dec 3, 2020

F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial »

Nov 24, 2020

F-star Therapeutics Announces Approval of Clinical Trial Application for FS222 »

Nov 20, 2020

F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals »

Nov 11, 2020

F-star Therapeutics to Present New Clinical and Mechanistic Data on its LAG-3/PD-L1 Tetravalent Bispecific Antibody, FS118, at the SITC 2020 Virtual Annual Meeting »

Oct 22, 2020

F-star Therapeutics to Present at SITC 2020 Virtual Annual Meeting »

Sep 9, 2020

F-star Therapeutics to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference »

Aug 5, 2020

F-star Therapeutics to Participate in BTIG Virtual Biotechnology Conference »

Jul 30, 2020

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies »

Jul 16, 2020

Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration »

Jun 22, 2020

F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting »

Apr 28, 2020

F-star Therapeutics Announces Positive Preclinical Antitumor Activity and Safety of FS222 Published in Clinical Cancer Research »

Apr 16, 2020

A Novel Mechanism of Action for FS118 and the Potential to Overcome PD-(L)1 Resistance Published in Clinical Cancer Research »

Apr 9, 2020

F-star Therapeutics Announces Data on Potent Anti-Tumor Activity of FS120 Published in Cancer Immunology Research »

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Others